docetaxel + CB-839

**docetaxel + CB-839** is a combination therapy consisting of **docetaxel**, a chemotherapy drug that functions as a microtubule inhibitor, and **CB-839** (telaglenastat), a first-in-class, potent, selective, and orally bioavailable small molecule inhibitor of glutaminase (GLS1). CB-839 inhibits glutaminase, blocking the conversion of glutamine to glutamate, thereby disrupting cancer cell metabolism and growth. The combination is under investigation for treating various advanced solid tumors, notably non-small cell lung cancer (NSCLC) with KRAS mutations, among other malignancies. The primary goal is to exploit the combination of metabolic intervention (by CB-839) with cytotoxic chemotherapy (docetaxel) to enhance anticancer efficacy[1][4][5].

Other names

docetaxel + telaglenastat